MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis (Q39447204)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis (English)

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

0 references

apoptotic process

0 references

allosteric inhibitor

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Yan Cheng

1

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Yi Zhang

2

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Li Zhang

3

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Xingcong Ren

4

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Kathryn J Huber-Keener

5

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Xiaoyuan Liu

6

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Lei Zhou

7

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Jason Liao

8

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Heike Keihack

9

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Li Yan

10

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Eric Rubin

11

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Jin-Ming Yang

12

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

4 November 2011

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Molecular Cancer Therapeutics

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

11

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

1

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

154-164

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

Combination therapy for malignant glioma based on PTEN status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

EGFR antagonists in cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

AKT/PKB signaling: navigating downstream

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

Doctor Jekyll and Mister Hyde: autophagy can promote both cell survival and cell death

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

Cell signaling by receptor tyrosine kinases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

12 September 2017

Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

14 September 2017

Role of Survivin in EGFR Inhibitor–Induced Apoptosis in Non–Small Cell Lung Cancers Positive for EGFR Mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

14 September 2017

Rapamycin protects against rotenone-induced apoptosis through autophagy induction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

14 September 2017

An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

14 September 2017

Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

14 September 2017

Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

14 September 2017

Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

14 September 2017

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

14 September 2017

Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

14 September 2017

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

21 August 2018

Gefitinib concentrations in human glioblastoma tissue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

21 August 2018

A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

21 August 2018

Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

21 August 2018

AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

21 August 2018

Gefitinib accumulation in glioblastoma tissue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

21 August 2018

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

21 August 2018

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302182

21 August 2018

Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells.

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.1158/1535-7163.MCT-05-0299

Identifiers

10.1158/1535-7163.MCT-11-0606

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

release_4kb6oxmnmnbjhlwzbv2tvl76x4

1 reference

https://api.fatcat.wiki/v0/release/4kb6oxmnmnbjhlwzbv2tvl76x4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39447204&oldid=2044960548"